By Amy Orciari Herman
The American Society of Hematology has issued new guidelines on managing venous thromboembolism.
Of the 28 recommendations, published in Blood Advances, 3 are classified as “strong”:
- For patients with pulmonary embolism (PE) and hemodynamic compromise, thrombolytic therapy followed by anticoagulation is recommended over anticoagulation alone.
- For those with deep venous thrombosis (DVT) or PE who have finished primary treatment and will continue a vitamin K antagonist for secondary prevention, an INR range of 2.0–3.0 should be used rather than a lower range.
- For patients with recurrent unprovoked DVT or PE, continuing antithrombotic therapy indefinitely is advised rather than stopping anticoagulation after primary treatment.
The “conditional” recommendations include the following: